Clinical Trial Update: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Arikayce in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pseudomonas Aeruginosa Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-06-24